How many of you use Spiriva HandiHaler for long-term maintenance treatment of your COPD? Now, there's is one more reason to continue to do so.
Based on data from two clinical trials (UPLIFT and Veteran's Affairs) and over 8,000 patients, Spiriva HandiHaler (tiotropium oral powder for inhalation) has been approved by the FDA for the reduction of exacerbations in patients with COPD.
While the UPLIFT trial failed to demonstrate as it had hoped, that Spiriva Handihaler could slow lung function decline, results demonstrated that it sustained improved lung function over 4 years when compared to placebo and reduced COPD exacerbations.
If you are currently not using Spiriva HandiHaler for COPD maintenance, now is the time you might want to talk with your doctor about the possibility of adding it to your treatment regimen. For more information about the study, visit Spiriva HandiHaler approved for the reduction of COPD exacerbations - MPR.
